Biochemical and Pharmacological Characterizations of ESI-09 Based EPAC Inhibitors: Defining the ESI-09 "Therapeutic Window"

Yingmin Zhu, Haijun Chen, Stephen Boulton, Fang Mei, Na Ye, Giuseppe Melacini, Jia Zhou, Xiaodong Cheng

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The cAMP signaling cascade is one of the most frequently targeted pathways for the development of pharmaceutics. A plethora of recent genetic and pharmacological studies suggest that exchange proteins directly activated by cAMP (EPACs) are implicated in multiple pathologies. Selective EPAC inhibitors have been recently developed. One specific inhibitor, ESI-09, has been shown to block EPAC activity and functions, as well as to recapitulate genetic phenotypes of EPAC knockout mice when applied in vivo. However, a recent study raised concern that ESI-09 might act as a non-specific protein denaturant. Herein, we present a detailed biochemical and pharmacological characterization, as well as a structure-activity relationship (SAR) analysis of ESI-09. Our studies show that ESI-09 dose-dependently inhibits activity of both EPAC1 and EPAC2 with apparent IC50 values well below the concentrations shown to induce "protein denaturation". Moreover, the ESI-09's action towards EPAC proteins is highly sensitive to minor modifications of the 3-chlorophenyl moiety. Taken together, these results demonstrate that ESI-09 indeed acts as an EPAC specific antagonist and does not significantly destabilize/denature proteins at pharmacological effective concentrations. This conclusion is further supported by NMR data showing that ESI-09 induces residue-dependent chemical shift changes at low concentrations, while preserving well dispersed peaks.

Original languageEnglish (US)
Article number9344
JournalScientific Reports
Volume5
DOIs
StatePublished - Mar 23 2015

Fingerprint

Pharmacology
Proteins
Therapeutics
Protein Denaturation
3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile
Structure-Activity Relationship
Knockout Mice
Inhibitory Concentration 50
Pathology
Phenotype
Pharmaceutical Preparations

ASJC Scopus subject areas

  • General

Cite this

Biochemical and Pharmacological Characterizations of ESI-09 Based EPAC Inhibitors : Defining the ESI-09 "Therapeutic Window". / Zhu, Yingmin; Chen, Haijun; Boulton, Stephen; Mei, Fang; Ye, Na; Melacini, Giuseppe; Zhou, Jia; Cheng, Xiaodong.

In: Scientific Reports, Vol. 5, 9344, 23.03.2015.

Research output: Contribution to journalArticle

Zhu, Yingmin ; Chen, Haijun ; Boulton, Stephen ; Mei, Fang ; Ye, Na ; Melacini, Giuseppe ; Zhou, Jia ; Cheng, Xiaodong. / Biochemical and Pharmacological Characterizations of ESI-09 Based EPAC Inhibitors : Defining the ESI-09 "Therapeutic Window". In: Scientific Reports. 2015 ; Vol. 5.
@article{6092b884efc5411aafa1f22eb85c3b75,
title = "Biochemical and Pharmacological Characterizations of ESI-09 Based EPAC Inhibitors: Defining the ESI-09 {"}Therapeutic Window{"}",
abstract = "The cAMP signaling cascade is one of the most frequently targeted pathways for the development of pharmaceutics. A plethora of recent genetic and pharmacological studies suggest that exchange proteins directly activated by cAMP (EPACs) are implicated in multiple pathologies. Selective EPAC inhibitors have been recently developed. One specific inhibitor, ESI-09, has been shown to block EPAC activity and functions, as well as to recapitulate genetic phenotypes of EPAC knockout mice when applied in vivo. However, a recent study raised concern that ESI-09 might act as a non-specific protein denaturant. Herein, we present a detailed biochemical and pharmacological characterization, as well as a structure-activity relationship (SAR) analysis of ESI-09. Our studies show that ESI-09 dose-dependently inhibits activity of both EPAC1 and EPAC2 with apparent IC50 values well below the concentrations shown to induce {"}protein denaturation{"}. Moreover, the ESI-09's action towards EPAC proteins is highly sensitive to minor modifications of the 3-chlorophenyl moiety. Taken together, these results demonstrate that ESI-09 indeed acts as an EPAC specific antagonist and does not significantly destabilize/denature proteins at pharmacological effective concentrations. This conclusion is further supported by NMR data showing that ESI-09 induces residue-dependent chemical shift changes at low concentrations, while preserving well dispersed peaks.",
author = "Yingmin Zhu and Haijun Chen and Stephen Boulton and Fang Mei and Na Ye and Giuseppe Melacini and Jia Zhou and Xiaodong Cheng",
year = "2015",
month = "3",
day = "23",
doi = "10.1038/srep09344",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Biochemical and Pharmacological Characterizations of ESI-09 Based EPAC Inhibitors

T2 - Defining the ESI-09 "Therapeutic Window"

AU - Zhu, Yingmin

AU - Chen, Haijun

AU - Boulton, Stephen

AU - Mei, Fang

AU - Ye, Na

AU - Melacini, Giuseppe

AU - Zhou, Jia

AU - Cheng, Xiaodong

PY - 2015/3/23

Y1 - 2015/3/23

N2 - The cAMP signaling cascade is one of the most frequently targeted pathways for the development of pharmaceutics. A plethora of recent genetic and pharmacological studies suggest that exchange proteins directly activated by cAMP (EPACs) are implicated in multiple pathologies. Selective EPAC inhibitors have been recently developed. One specific inhibitor, ESI-09, has been shown to block EPAC activity and functions, as well as to recapitulate genetic phenotypes of EPAC knockout mice when applied in vivo. However, a recent study raised concern that ESI-09 might act as a non-specific protein denaturant. Herein, we present a detailed biochemical and pharmacological characterization, as well as a structure-activity relationship (SAR) analysis of ESI-09. Our studies show that ESI-09 dose-dependently inhibits activity of both EPAC1 and EPAC2 with apparent IC50 values well below the concentrations shown to induce "protein denaturation". Moreover, the ESI-09's action towards EPAC proteins is highly sensitive to minor modifications of the 3-chlorophenyl moiety. Taken together, these results demonstrate that ESI-09 indeed acts as an EPAC specific antagonist and does not significantly destabilize/denature proteins at pharmacological effective concentrations. This conclusion is further supported by NMR data showing that ESI-09 induces residue-dependent chemical shift changes at low concentrations, while preserving well dispersed peaks.

AB - The cAMP signaling cascade is one of the most frequently targeted pathways for the development of pharmaceutics. A plethora of recent genetic and pharmacological studies suggest that exchange proteins directly activated by cAMP (EPACs) are implicated in multiple pathologies. Selective EPAC inhibitors have been recently developed. One specific inhibitor, ESI-09, has been shown to block EPAC activity and functions, as well as to recapitulate genetic phenotypes of EPAC knockout mice when applied in vivo. However, a recent study raised concern that ESI-09 might act as a non-specific protein denaturant. Herein, we present a detailed biochemical and pharmacological characterization, as well as a structure-activity relationship (SAR) analysis of ESI-09. Our studies show that ESI-09 dose-dependently inhibits activity of both EPAC1 and EPAC2 with apparent IC50 values well below the concentrations shown to induce "protein denaturation". Moreover, the ESI-09's action towards EPAC proteins is highly sensitive to minor modifications of the 3-chlorophenyl moiety. Taken together, these results demonstrate that ESI-09 indeed acts as an EPAC specific antagonist and does not significantly destabilize/denature proteins at pharmacological effective concentrations. This conclusion is further supported by NMR data showing that ESI-09 induces residue-dependent chemical shift changes at low concentrations, while preserving well dispersed peaks.

UR - http://www.scopus.com/inward/record.url?scp=84925424433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925424433&partnerID=8YFLogxK

U2 - 10.1038/srep09344

DO - 10.1038/srep09344

M3 - Article

C2 - 25791905

AN - SCOPUS:84925424433

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 9344

ER -